Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Executive Summary

Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years
Advertisement

Related Content

Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck U.S. Restructuring Not To Blame For Q1 Sales Drop, Execs Say
Merck’s Ambitious Plans For Follow-On Biologics
Merck’s Ambitious Plans For Follow-On Biologics
As Sales Slip, Merck & Co. Plans 7,200 Job Cuts
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
Merck Revises Guidance To Include $700 Million Less In Vytorin/Zetia Sales
Advertisement
UsernamePublicRestriction

Register

PS050476

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel